Krishna Institute of Medical Sciences (KIMS) is consolidating at speed. The hospital chain's board has approved acquisitions worth a combined ₹135 crore across four healthcare companies, The Hindu BusinessLine reported on October 7 — one of the busiest single-day inorganic pushes by an Indian hospital chain this year.
The four moves: a 22% stake in Splendid Hospitals for ₹40 crore; up to 51% of Insignia Healthcare, the Guntur-based operator of a 150-bed hospital (expandable to 200 beds); a 6% stake in Ushahkal Abhinav Specialty Hospital for ₹15 crore; and a 51% stake in Sarvottam Health Care, which runs the Kakinada-based Trust Multi Speciality Hospital, for ₹80 crore — a deal expected to close by October 31, 2026.
The pattern is deliberate. KIMS already manages the Insignia and Sarvottam facilities under operations-and-maintenance agreements; the acquisitions convert those O&M relationships into majority equity ownership. The Insignia deal will be executed as a creeping acquisition over 12 to 24 months at an initial ₹30.35 per share, based on a BDO valuation report. Ushahkal Abhinav, a 316-bed quaternary-care hospital on a 4-acre campus with headroom to 500 beds, deepens KIMS's footprint in Maharashtra's Sangli–Miraj–Kupwad medical cluster, alongside its Nagpur, Nashik and upcoming Thane facilities.
The ₹80-crore Sarvottam deal, for a target with ₹84.83 crore in FY2025-26 turnover, is the anchor transaction — KIMS shifts from collecting a management fee to owning the asset's full earnings stream.
Why it matters for founders
KIMS is executing a textbook regional roll-up: test a market with an asset-light O&M contract, prove the operating model, then deploy balance-sheet capital for equity control. If you're building in healthcare services, this is the consolidation wave to surf — strong regional operators with 100-300 beds are exactly the profile acquirers want, and O&M partnerships are the proving ground that converts into buyouts.